{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:29Z","timestamp":1788243389535,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02350-w","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:02:39Z","timestamp":1783396959000},"page":"1563-1570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ecnoglutide: First Approvals"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"10531","key":"2350_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tschop MH, et al. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892\u2013908.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2350_CR2","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.2337\/dc26-S008","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20132026. Diabetes Care. 2026;49(Suppl 1):S166\u201382.","journal-title":"Diabetes Care"},{"issue":"11","key":"2350_CR3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Tirzepatide: first approval. Drugs. 2022;82(11):1213\u201320.","journal-title":"Drugs"},{"issue":"12","key":"2350_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-025-02249-y","volume":"85","author":"M Shirley","year":"2025","unstructured":"Shirley M. Mazdutide: first approval. Drugs. 2025;85(12):1621\u20137.","journal-title":"Drugs"},{"key":"2350_CR5","unstructured":"Sciwind Biosciences. Sciwind Biosciences announces ecnoglutide injection approved by China\u2019s National Medical Products Administration (NMPA) for chronic weight management [media release]. 06 Mar 2026. https:\/\/www.sciwindbio.com\/portal\/index\/newsdetail\/id\/125\/category_id\/5.html."},{"key":"2350_CR6","unstructured":"Sciwind Biosciences. Sciwind Biosciences announces ecnoglutide injection approved by China\u2019s National Medical Products Administration (NMPA) for adult type 2 diabetes [media release]. 30 Jan 2026. https:\/\/www.sciwindbio.com\/portal\/index\/newsdetail\/id\/122\/category_id\/5.html."},{"key":"2350_CR7","unstructured":"Pfizer. Ecnoglutide injection for long-term weight management: Chinese prescribing information [Chinese]. 2026. https:\/\/pfizermedicalinformation.cn\/srd\/download-document\/a0rbi00000oDwnrAAC. Accessed 19 May 2026."},{"key":"2350_CR8","unstructured":"Pfizer. Ecnoglutide injection for type 2 diabetes: Chinese prescribing information [Chinese]. 2026. https:\/\/pfizermedicalinformation.cn\/srd\/download-document\/a0rbi00000kCN6VAAW. Accessed 05 Jun 2026."},{"key":"2350_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101762","volume":"75","author":"W Guo","year":"2023","unstructured":"Guo W, Xu Z, Zou H, et al. Discovery of ecnoglutide\u2014a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023;75:101762.","journal-title":"Mol Metab"},{"issue":"9","key":"2350_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S2213-8587(25)00157-3","volume":"13","author":"TMM Tan","year":"2025","unstructured":"Tan TMM. Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues? Lancet Diabetes Endocrinol. 2025;13(9):728\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2350_CR11","unstructured":"Sciwind Biosciences. Sciwind Biosciences and HK inno.N Corporation announce licensing and partnership agreement for ecnoglutide injection (XW003) in South Korea [media release]. 07 May 2024. https:\/\/www.sciwindbio.com\/portal\/index\/newsdetail\/id\/101\/category_id\/5.html."},{"key":"2350_CR12","unstructured":"Sciwind Biosciences. Sciwind Biosciences announces global licensing and collaboration agreement for metabolic disease portfolio [media release]. 10 Jan 2025. https:\/\/www.sciwindbio.com\/portal\/index\/newsdetail\/id\/98\/category_id\/5.html."},{"key":"2350_CR13","unstructured":"Sciwind Biosciences. Sciwind Biosciences partners with Pfizer China to commercialize its biased GLP-1 in China [media release]. 24 Feb 2026. https:\/\/www.sciwindbio.com\/portal\/index\/newsdetail\/id\/123\/category_id\/5.html."},{"issue":"1","key":"2350_CR14","doi-asserted-by":"publisher","first-page":"8408","DOI":"10.1038\/s41467-024-52353-y","volume":"15","author":"D Zhu","year":"2024","unstructured":"Zhu D, Wang W, Tong G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024;15(1):8408.","journal-title":"Nat Commun"},{"issue":"1","key":"2350_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68165-7","volume":"17","author":"D Zhu","year":"2026","unstructured":"Zhu D, Wang W, Tong G, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026;17(1):1420.","journal-title":"Nat Commun"},{"issue":"10","key":"2350_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-8587(25)00196-2","volume":"13","author":"Y He","year":"2025","unstructured":"He Y, Mi N, Cheng Z, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(10):863\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2350_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S2213-8587(25)00141-X","volume":"13","author":"L Ji","year":"2025","unstructured":"Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(9):777\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2350_CR18","doi-asserted-by":"crossref","unstructured":"Zhu Z, Li Y, Zheng Q, et al. An open-label, active-controlled phase 2 evaluation of novel GLP-1 analog ecnoglutide in adults with obesity. Diabetes. 2023;72(Suppl 1):79\u2013LB.","DOI":"10.2337\/db23-79-LB"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02350-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02350-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02350-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:38Z","timestamp":1788242558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02350-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2350"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02350-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}